All In Biotech

Drug Trial Radar · NCT00699751

A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases

Last checked: Nov 20, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 921 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

921

Actual

Start

Jun 12, 2008

Primary completion

Jul 15, 2011

Study completion Feb 13, 2014

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.

Conditions

  • Hormone Refractory Prostate Cancer
  • Bone Metastases

Interventions

  • Radium-223 dichloride (Xofigo, BAY88-8223)Drug

    Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.

  • PlaceboDrug

    Isotonic saline 6 IV administrations separated by 4 weeks intervals.

  • Best standard of care (BSoC)Drug

    Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: From randomization to death due to any cause until approximately 3 years after start of enrollment, the data was collected up to the second data analysis date (15 JUL 2011)

Locations

134 sites in 19 countries. Site status is shown where the registry gives one.

  • Site not named

    Los Angeles, California

  • Site not named

    Roseville, California

  • Site not named

    Tampa, Florida

  • Site not named

    New Orleans, Louisiana

  • Site not named

    St Louis, Missouri

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Liverpool, New South Wales, Australia

  • Site not named

    Randwick, New South Wales, Australia

  • Site not named

    St Leonards, New South Wales, Australia

  • Site not named

    Sydney, New South Wales, Australia

  • Site not named

    Wahroonga, New South Wales, Australia

  • Site not named

    Wollongong, New South Wales, Australia

  • Site not named

    Herston, Queensland, Australia

  • Site not named

    Toowoomba, Queensland, Australia

  • Site not named

    Adelaide, South Australia, Australia

  • Site not named

    Woodville South, South Australia, Australia

  • Site not named

    Hobart, Tasmania, Australia

  • Site not named

    Fitzroy, Victoria, Australia

  • Site not named

    Nedlands, Western Australia, Australia

  • Site not named

    Kortrijk, Belgium

  • Site not named

    Ottignies, Belgium

  • Site not named

    Belo Horizonte, Brazil

  • Site not named

    Salvador, Estado de Bahia, Brazil

  • Site not named

    Belo Horizonte, Minas Gerais, Brazil

  • Site not named

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Site not named

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site not named

    Barretos, São Paulo, Brazil

  • Site not named

    Piracicaba, São Paulo, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    Edmonton, Alberta, Canada

  • Site not named

    London, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Brno, Czechia

  • Site not named

    Chomutov, Czechia

  • Site not named

    Olomouc, Czechia

  • Site not named

    Ostrava, Czechia

  • Site not named

    Plzen - Bory, Czechia

  • Site not named

    Prague, Czechia

Showing 40 of 134 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.